Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants
Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
Mobile Health Tool Helps Improve Quality of Life For Young Breast Cancer Survivors
Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer
Triplet Therapy Shows Promise for BPDCN, a rare blood cancer, in Dana-Farber Study
Childhood leukemia care puts one in three families at risk of poverty
Dana-Farber Cancer Institute drives deep remissions in Waldenstrom’s with targeted, time limited therapies
Chemo-free Regimens Show Promise, Could Redefine Care for B-Cell Lymphomas
Phase III VERONA trial results show potential benefit for some groups with myelodysplastic syndrome (MDS)
Sickle-cell disease associated with early onset of clonal hematopoiesis, a precancerous condition
Dana-Farber researchers present findings at 2025 San Antonio Breast Cancer Symposium
Dana-Farber Research Opens the Door to Finding More Effective Treatments for Ewing Sarcoma
Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer
Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers
Dana-Farber Research Points to Potential Gene Therapy Improvements
Showing 1 - 15 of 1055 results
Previous| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ...71 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
